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Recent community- and hospital-based studies ofepilepsy from its onset suggest a much better
prognosis than previously recognized, with about three-quarters of patients entering long-term
remission on current medication. The first two years of medication are crucial in determining
longer-term prognosis. Early effective therapy may be important in preventing the evolution of
chronic epilepsy. Adverse prognostic factors include brain lesions, neuropsychiatric handicaps,
and poor compliance.
PROGNOSIS OF EPILEPSY
The traditional and rather gloomy view ofprognosis was summarized in the detailed
review by Rodin [1] which spans the period from Gowers [2], who first applied a
statistical approach to prognosis in the late nineteenth century, to Rodin's own
valuable studies. Rodin concluded that only approximately one-third of epileptic
patients are likely to achieve a terminal remission ofat least two years; that the longer
patients are followed up, the more likely is relapse to occur; and that 80 percent ofall
patients with epilepsy are likely to have a chronic seizure disorder. Although the latter
does not rule out short-term remissions, it emphasizes that epilepsy should be regarded
as a chronic condition with remissions and exacerbations. Rodin recognized that his
review was based almost wholly on studies of chronic patients in institutions or
attending special outpatient clinics. He noted that the longer the history of epilepsy
prior to hospital consultation the worse the prognosis, and he rightly drew attention to
the good prognosis reported by Gowers [2] in patients with a short history of epilepsy
treated with bromides. At the time ofhis review there had been no systematic study of
epilepsy at its onset and, as Shorvon [3] has pointed out, a weakness or source of
misunderstanding in the studies reviewed was a failure to appreciate certain temporal
aspects of the development of epilepsy, arising from the retrospective, cross-sectional
nature ofthe investigations, based on heterogeneous populations ofpatients with a very
variable duration ofillness. Another interesting feature ofthe period, approximately a
century, reviewed by Rodin was the introduction and useofmany major anticonvulsant
drugs of undoubted efficacy, from bromides, through barbiturates, to hydantoins,
succinamides, and carbamazepine, most of which are still widely prescribed today.
Rodin questioned whether there had been any improvement in overall prognosis
throughout this time. A factor which was and still is missing in our understanding of
prognosis is any information about the prognosis of untreated epilepsy. Practice was
and still is perhaps influenced by Gowers's [2] view that the spontaneous cessation of
the disease was an event too rare to be reasonably anticipated in any given case.
In the last decade new studies have focused attention on epilepsy as viewed and
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followed from the onset ofthe disorder, both in the community and the hospital clinic.
This has given some new insights into the temporal evolution of epilepsy, dispelled
someofthe gloomier views ofprognosis based on studies ofchronic patients, and raised
some fundamental questions about the nature and treatment ofepilepsy, which will be
discussed in this review.
COMMUNITY-BASED STUDIES
Prevalence rates for active epilepsy vary from 4 to 10/1,000, depending on
definitions and methods of study [4]. If, however, up to 5 percent of the general
population may at some timeexperience a non-febrile seizure, as has been reported [5],
this suggests that most of them do not go on to develop chronic epilepsy. In keeping
with this, Goodridge and Shorvon [6] found that the lifetime prevalence of epilepsy
(excluding febrile convulsions but including single seizures) was 20.2/1,000, whereas
the prevalence ofcontinuing "active" epilepsy was 5.3/1,000.
Annegers et al. [7] retrospectively reviewed the prognosisof475 patients who had an
initial diagnosis of epilepsy recorded on the Mayo Clinic record linkage system
between 1935 and 1974. In contrast to Rodin's observations, remission rates improved
with duration of follow-up, and in those followed for 20 years as many as 70 percent
were in five-year remission, and 50 percent had withdrawn medication. Goodridge and
Shorvon [6] reviewed the general practice records of a population of 6,000 in Kent,
U.K. Of 122 patients identified with at least one non-febrile seizure (82 percent of
which were recurrent), 69 percent were in a four-year remission at 15 years of
follow-up.
The much more favorable picture of prognosis emerging from these retrospective
community-based studies is also supported by our own hospital-based studies of
patients followed prospectively from the onset oftheir epilepsy over the last ten years.
PROSPECTIVE STUDY OF NEWLY DIAGNOSED EPILEPSY
In the past decade my colleagues and I have followed prospectively 106 adolescent or
adult patients with newly diagnosed, previously untreated epilepsy referred to the
neurology department at Kings College Hospital, a district general hospital in London
[8,9]. Each patient had had at least two tonic clonic or partial seizures in the past year.
Treatment was with monotherapy with either phenytoin (61 patients) or carbamaze-
pine (45 patients), initially in a small dose. Serum levels of the drugs were monitored
regularly. Ifseizures recurred the dosage was increased, ifnecessary into the optimum
blood level range. The occurrence of two or more seizures despite an optimum serum
level of phenytoin or carbamazepine was regarded as evidence of failure of monother-
apy and a second drug was added. The median duration of follow-up was 66 months
(range, 6-96 months).
The overall prognosis for this population was very good: 73 percent were in one-year
remission by two years offollow-up, 88 perecent by four years, and 92 percent by eight
years; the pattern for two-year remission rates was similar with 73 percent in two-year
remission by four years of follow-up and 82 percent by eight years. There were 79
patients in whom seizures were controlled for two years and subsequent follow-up data
were available in 76; 51 percent remained completely seizure-free for the rest of
follow-up; 25 had a recurrence of seizures, which consisted of only two attacks in 17
and was related to poor compliance in 16.
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Factors Influencing Prognosis
A number offactors had an adverse effect on remission rates. These included partial
as compared with tonic clonic seizures, a high frequency oftonic clonic seizures before
treatment, a family history of seizures, and, most significantly, the presence of
additional neurological, psychiatric, or social handicaps. In general these adverse
prognostic factors are similar to those identified in studies ofchronic patients [I]. Only
21 ofour patients failed to respond to monotherapy, and none ofthem benefitted from
the addition of a second drug. Interestingly, 19 of the monotherapy failures occurred
within the first two years of treatment, and there were only two late failures. We
compared the 21 treatment failures with 21 treatment responders out of the original
population of 106, carefully matched for age, sex, seizure, and treatment variables
[10]. Two factors emerged which were clearly associated with failure ofmonotherapy:
poor compliance and the presence ofcerebral pathology.
The Influence ofEarly Treatment
Even in the presence of adverse prognostic factors such as partial seizures and
additional neuropsychiatric handicaps, the majority of our patients went into one- or
two-year remission. It therefore seemed probable that other unidentified factors might
contribute to treatment failure and a poor prognosis. One such possible factor which
interests us is the influence ofearly treatment and response on later prognosis [8,9,1 1].
We have shown that the longer seizures continue after the onset of treatment the less
likely is the patient to go into remission. Thus for the patient still having seizures two
years after the onset of treatment the subsequent one-year remission rate is approxi-
mately halved. The first two years of treatment are very important in relation to
longer-term prognosis, and it is interesting that all our patients who failed to respond to
optimum single-drug therapy within this period went on to develop chronic epilepsy.
This data is open to two possible interpretations [11]. First, perhaps, those patients
who fail to go into remission and develop chronic epilepsy have inherently more
"severe" epilepsy, so "severe" that they cannot be controlled by currently available
medication. The concept of "severe" epilepsy, however, especially in a patient
presenting with his or her first few seizures, is a difficult one, the clarification ofwhich
would require prolonged observation ofuntreated patients, which for ethical reasons is
unlikely to be undertaken. Furthermore, there is little doubt that in many individual
patients epilepsy may appear to be either "severe"" or "mild" at different times. An
alternative explanation which I prefer is to regard epilepsy as a process in which there
are less apparent cerebral events between the visible seizures and which may remit
spontaneously or under the influence of anticonvulsant treatment. That remission is
not always simply a matter ofdrug treatment is illustrated by the well-known tendency
for some seizure types, such as petit mal or certain benign epilepsies of childhood, to
remit spontaneously. In chronic epilepsy, this process evolveserratically or progessively
out ofcontrol, such that it becomes unresponsive to currently available medication.
One mechanism which might underlie the evolution of chronic epilepsy was
suggested by Gowers a century ago. He commented that "when one attack has
occurred, whether in apparent consequence of an immediate excitant or not, others
usually follow without any immediate traceable cause. The effect of a convulsion on
the nerve centres is such as to render the occurrence ofanother more easy, to intensify
the predisposition that already exists. Thus every fit may be said to be, in part, the
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result ofthose which have preceded it, the causeofthose which follow it." He presented
evidence from his own careful observations that the prognosis for seizure control was
inversely proportional to the duration of the disorder. He emphasized the very
favorable prognosis in patients with a seizure disorder ofless than one year (83 percent
"arrested") and the relatively high probability that seizures would not be controlled if
the disorder had been present for more than five years. Shorvon [3] has summarized
other recent studies ofmonotherapy with currently available drugs in relatively smaller
numbers ofnewly diagnosed epileptic patients followed up for no more than two years,
which have confirmed the good prognosis in such patients.
Other possible evidence in favor ofan evolving process ofepilepsy has come from an
analysis of the time intervals between attacks in those patients presenting to us at a
neurological clinic with three or more untreated tonic clonic seizures [12]. There is a
remarkable decline in the interval between successive seizures which we observe in the
vast majority of such referrals. The data is retrospective, however, and it is possible
that patients with lengthening intervals between seizures are less likely to be referred
to hospital. On the other hand, Goodridge and Shorvon [6] found that the great
majority ofpatients with newly diagnosed epilepsy are referred to hospital.
The possible implication ofour studies and those ofGowers [2] is that the process of
epilepsy should be treated early and effectively to prevent the development of chronic
epilepsy [11]. Once chronic epilepsy is established, especially after the first two years,
it becomes very difficult to treat.
CONCLUSIONS
Recent retrospective community-based studies and our own hospital-based prospec-
tivestudies ofnewly diagnosed epileptic patients over the last ten years suggest that the
overall prognosis for epilepsy is much more favorable than has been implied from
previous hospital- and institution-based investigations. The unduly gloomy view of
prognosis which emerged from the latter studies was due to the accumulation of
chronic patients in such clinics. In fact, some three-quarters of new, previously
untreated referrals can expect to be controlled by currently available medication. As
epilepsy is so common, the approximately 25 percent of patients who go on to develop
chronic epilepsy still represent an enormous burden on and challenge to Health
Services, as chronic epilepsy is so difficult to treat.
The first two years of treatment are crucial, and most patients who go on to develop
chronic epilepsy can be identified within this period. Factors which contribute to
failure of treatment and the evolution of chronic epilepsy are the presence of brain
lesions and neuropsychiatric handicaps, and especially poor compliance. In addition,
there is some evidence to suggest that epilepsy should be regarded as a process, which
in many patients has a tendency to escalate, perhaps by the mechanism proposed by
Gowers, unless arrested by treatment. Early effective treatment associated with good
compliance may thus be important in the prevention ofchronic epilepsy.
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